Literature DB >> 11738869

The role of X-chromosome inactivation in the manifestation of Rett syndrome.

N Takagi1.   

Abstract

X-chromosome inactivation (XCI) is random in the majority of patients with classical Rett syndrome (RTT). Preferential inactivation of the X chromosome with the mutated MECP2 gene is found in mildly symptomatic or asymptomatic carrier females. These findings lead to a hypothesis that random XCI is causally involved in the pathogenesis of RTT in heterozygous females. It is the cluster of functionally defective nerve cells lacking fully functional MeCP2 generated by inactivation of normal MECP2 allele that causes the wide spectrum of RTT symptoms. Thus, RTT is a rare human disease manifestation which is triggered most probably by random XCI.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11738869     DOI: 10.1016/s0387-7604(01)00362-x

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  3 in total

1.  Engineered microRNA-based regulatory element permits safe high-dose miniMECP2 gene therapy in Rett mice.

Authors:  Sarah E Sinnett; Emily Boyle; Christopher Lyons; Steven J Gray
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

2.  Deletion of Mecp2 in Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, and the response to stress.

Authors:  Sharyl L Fyffe; Jeff L Neul; Rodney C Samaco; Hsiao-Tuan Chao; Shay Ben-Shachar; Paolo Moretti; Bryan E McGill; Evan H Goulding; Elinor Sullivan; Laurence H Tecott; Huda Y Zoghbi
Journal:  Neuron       Date:  2008-09-25       Impact factor: 17.173

3.  MRX87 family with Aristaless X dup24bp mutation and implication for polyAlanine expansions.

Authors:  Carmela Laperuta; Letizia Spizzichino; Pio D'Adamo; Jlenia Monfregola; Antonio Maiorino; Angela D'Eustacchio; Valerio Ventruto; Giovanni Neri; Michele D'Urso; Pietro Chiurazzi; Matilde Valeria Ursini; Maria Giuseppina Miano
Journal:  BMC Med Genet       Date:  2007-05-04       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.